7月31日，Moderna盘中上涨5.03%，报57.23美元/股，成交额1.41亿美元。公司将于当日盘前发布二季度财报，叠加近期多家机构密集上调目标价及管线利好催化。
消息面上，高盛于7月20日将Moderna目标价从49美元大幅上调至67美元，维持中性评级；杰富瑞于7月13日上调至60美元；Piper Sandler此前上调至77美元并维持增持。此外，公司季节性流感疫苗候选产品mRNA-1010获FDA咨询委员会9票赞成、0票反对的一致支持，最终审批结果预计8月5日公布。管线方面，公司肿瘤靶向癌症抗原疗法一期临床已完成首例患者给药，多元化布局持续推进。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.